Head-To-Head Survey: Ginkgo Bioworks (NYSE:DNA) and Alpha Cognition (OTC:ACOGF)

Alpha Cognition (OTC:ACOGF) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Risk & Volatility

Alpha Cognition has a beta of 2.81, meaning that its stock price is 181% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Alpha Cognition and Ginkgo Bioworks, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	0	0	N/A
Ginkgo Bioworks	3	2	1	0	1.67

Ginkgo Bioworks has a consensus target price of $4.16, suggesting a potential downside of 46.32%. Given Ginkgo Bioworks’ higher possible upside, analysts plainly believe Ginkgo Bioworks is more favorable than Alpha Cognition.

Insider & Institutional Ownership

78.6% of Ginkgo Bioworks shares are held by institutional investors. 31.5% of Alpha Cognition shares are held by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Alpha Cognition and Ginkgo Bioworks”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	N/A	N/A	-$13.77 million	C($0.12)	-3.17
Ginkgo Bioworks	$251.46 million	1.71	-$892.87 million	($18.40)	-0.42

Alpha Cognition has higher earnings, but lower revenue than Ginkgo Bioworks. Alpha Cognition is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alpha Cognition and Ginkgo Bioworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-522.43%
Ginkgo Bioworks	-486.98%	-63.09%	-38.13%

About Alpha Cognition

Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.